| Description |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Himmel Pharma
|
Carboplatin 150mg/15ml |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Himmel Pharma |
|
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Himmel Pharma
|
Cisplatin 50mg/50ml
|
| Product Type |
Product Size |
| Tablet |
20'S |
| Product Company |
| Mass Pharma |
Amlodipine 5mg
|
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Sandoz |
|
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
AJM Pharmaceuticals |
|
| Content | Carboplatin is an alkylating agent used to treat advanced ovarian cancer.Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
| Etrombopag olamine product ingredient for etrombopag. It is used to treat low blood platelet counts in adults with chronic immune , thrombocytopenia or aplastic anemia. | Cisplatin is a platinum based chemotherapy agent used to treat various sarcomas, carcinomas, lymphomas and germ cell tumors.
| Amlodipine is in a class of medications called calcium channel blockers. It lowers blood pressure by relaxing the blood vessels so the heart does not have to pump as hard. It controls chest pain by increasing the supply of blood to the heart
| Gemcitabine is a cytidine analog with two fluorine atoms.As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells. | Gemcitabine is a nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer. |
Reviews
There are no reviews yet.